A copy of the full report, including the full set of key findings and its methodology, is available through USU Libraries Digital Commons
The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditionsof aging: implications for cognitive health 13
The specific dosage and frequency should be determined by a healthcare provider based on individual needs and medical history
Protocol 5: neurological recovery support Goal: Support recovery from TBI, stroke, or other neurological injury Primary peptide: Cerebrolysin 10-20ml IM daily for 10-20 days (requires medical supervision) Alternatively: Semax 600-900mcg daily if Cerebrolysin unavailable Supporting peptide: BPC-157 500mcg twice daily for tissue healing Duration: Acute phase treatment, may repeat cycles as recovery progresses Considerations: Neurological injury recovery should involve medical supervision
However, some potential side effects include: Mild nausea or stomach discomfort Temporary irritability Headaches Changes in appetite Sleep pattern changes Digestive issues Mood fluctuations Temporary anxiety Skin reactions Blood pressure changes When to Seek Medical Attention: Severe allergic reactions (rash, difficulty breathing) Persistent headaches lasting more than 48 hours Significant changes in mood or behavior Severe gastrointestinal symptoms Unusual heart rhythm or palpitations Safety Considerations: Research Stage: Dihexa remains in research phase, requiring more clinical trials Drug Interactions: Limited data on interactions with medications Individual Variation: Response and effects vary between people Long-term Effects: Extended use effects still being studied Medical Supervision: Usage should be monitored by healthcare professionals Summary In the landscape of nootropic and peptide therapies, Dihexa emerges as a compound with remarkable potential, particularly in the realm of cognitive enhancement and the treatment of neurodegenerative diseases
